By Denny Jacob
Shares of GeneDx Holdings shot up 24% following higher-than-expected revenue in its fourth quarter.
Shares were trading around $95. Over the last year, the stock is up nearly 1800%.
The patient health intelligence company recorded revenue of $95.3 million, up 64% from $58.1 million in the prior-year period. Analysts polled by FactSet had expected $82.2 million.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.